Search PubMed⌕ Search

Biomedical subjects

K Kanazawa

Publications and source records attributed to K Kanazawa.

At least 289 records · Page 16Linked to original sources
PubMed1984

[Clinical effects of human fibroblast interferon in advanced gynecological cancers].

Human fibroblast interferon (IFN-beta) was given 13 cases of advanced gynecological cancers. Eight patients, who were clinically evaluable, were reported as follows; Patients consisted of ovarian adenocarcinoma (5), cervical adenocarcinoma (1), endometrial carcinoma (1) and tubal carcinoma (1). Route of administration was intravenous in 5 cases and intratumorous in 3 cases. IFN-beta dose ranged from 2, 650 X 10(4) to 10, 620 X 10(4) units. Clinical effects according to Koyama - Saitoh 's category was progressive disease (PD) in 7 cases and minor response (MR) only in one case who received intratumorous injection for recurrent tumor mass of tubal carcinoma in vaginal stump. Side effects of IFN-beta were chill and fever, fatigue and anorexia, leucocyte--and thrombocyte-- penia and hepatic dysfunction, though they were mild in grade and not dose-limiting factors. No anti-IFN-beta-antibodies were detected in any cases.

Adenocarcinoma↗
PubMed1983

Congenital hydrocephalus revealed in the inbred rat, LEW/Jms.

We studied the development of congenital hydrocephalus found in a colony of an inbred strain of Wistar-Lewis rats (LEW/Jms) at various intervals after birth. The disorder was transmitted as a simple recessive mendelian character. Hydrocephalic neonates were recognized 2 days after birth by stretching of the skin over the head. Death usually occurred between 10 and 20 days of age. The findings suggested the possibility of a disturbance of cerebrospinal fluid circulation resulting from primary occlusion of the 3rd or lateral ventricles during embryological development. In later phases, the hydrocephalus was aggravated by obliteration of the subarachnoid space and by stenosis of the aqueduct occurring secondary to compression of these structures from increased pressure within the brain. In some animals, external hydrocephalus occurred as a result of rupture of the occipital pole and the establishment of a direct communication between the lateral ventricles and the subdural space. We looked for antibodies against viruses that have been known to produce hydrocephalus in experimental animals and obtained entirely negative results.

Animals↗
PubMed1983

[Studies of anti-lymphocyte antibodies, with special reference to anti-B cell antibodies in choriocarcinoma].

For the purpose of elucidation of the immunologic properties of anti-lymphocyte antibodies which appeared in sera of choriocarcinoma patients, HLA typing of lymphocytes, complement-dependent lymphocytotoxicity test (CT) and mixed lymphocyte reaction (MLR)-blocking assay with patients' sera were performed in 7 couples with the disease. The results obtained were as follows: HLA distribution characteristic of patients and their husbands was not observed. In 3 of 7 patients, their sera exhibited positive CT to their husband's lymphocyte. In MLR-blocking assay, a significant blocking effects (BE) with sera were detected in all patients. The serum BE tended to be sustained for 4 to 8 months even after the decline of serum beta-hCG into the negative range. It was also observed that a case in whom the BE was positive for a longer period of time in a state of remission eventually underwent recurrence. It was demonstrated that the BE and MLR was induced by serum IgG antibodies closely associated with surface antigens of the husband's B-lymphocyte. Consequently, it was strongly suggested that serum anti-lymphocyte antibodies immunologically reflect the tumour burden in choriocarcinoma patients.

Adult↗
PubMed1983

[Inhibitory effects of OK-432 and PSK on cell growth of in vitro human choriocarcinoma cell lines].

The cancer chemotherapy combined with immuno-potentiators, OK-432 and/or PSK, had yielded an improvement in survival rate of choriocarcinoma patients in our clinic as previously reported elsewhere. In the present study, for the purpose of evaluation of direct antitumor activity of OK-432 and PSK, inhibitory effects of the drugs on cell growth of GCH-1 and GCH-2 (in vitro cell lines of human choriocarcinoma) were analyzed referring to those of MTX (methotrexate) and Act-D (actinomycin D). 1) IC 50 (50% inhibitory concentration) of OK-432 and of PSK were 0.56 KE/ml on GCH-1 and 0.48 KE/ml on GCH-2, and 310 micrograms/ml on GCH-1 and 460 micrograms/ml on GCH-2, respectively. 2) The morphological changes of the target cells, observed by light and electron microscope, induced by OK-432 and PSK seemed to be not different from those by MTX and Act-D. 3) Serial changes of hCG levels in the culture media in which OK-432 or PSK was added were roughly comparable with those in MTX or Act-D. Thus, the direct antitumor activity of OK-432 and PSK on GCH-1 and GCH-2 was exquisitely weak judging from their IC50 and it was suggested that their direct antitumor effects in vivo might be clinically negligible in choriocarcinoma.

Animals↗
PubMed1982

[Clinical trial of cisplatin in the treatment of ovarian carcinoma].

Cisplatin (cis-diamminedichloroplatinum) was administered to 20 patients with histologically proven ovarian cancer. Ten of 20 patients were evaluable. They consisted of 1 patient by single use and 9 by combined use. The dose of cisplatin in single administration was 50 mg/m2, and the schedule for combined administration was as follows: cisplatin (50mg/m2, i.v. day 1), adriamycin (40 mg/m2, i.v. day 1), cyclophosphamide (350 mg/m2, i.v. day 1) and 5-FU (350 mg/m2, i.v. day 1-5). This was repeated every three weeks. The side effects of cisplatin and in its combination use were relatively severe. All of 20 patients showed severe nausea and vomiting, but fortunately there were no signs of hepatotoxicity, bone marrow or renal impairments during these courses. As the result, according to the response criteria of Koyama-Saito's group, out of 10 evaluable patients, the response rate consisting of partial and complete responses was 50% (CR: 3 cases, RP: 2 cases). It is shown that cisplatin is effective and useful in chemotherapy for the patients with ovarian carcinoma.

Adenocarcinoma↗
PubMed1982

[On the follow up period of postmolar patient (author's transl)].

We discussed how long should postmole patients be followed up by the analysis of 44 cases of postmolar invasive mole and 14 cases of postmolar choriocarcinoma treated in our hospital between 1971 and 1979. All of the invasive mole have been detected before their urinary hCG titer fell below normal pituitary LH level and by the 5 th month after the termination of molar pregnancy. While only 2 cases out of 14 cases of postmolar choriocarcinoma have been detected before their urinary hCG titer fell below LH level and by the 5 th postmole month. The other 12 cases of choriocarcinoma were diagnosed later than the 6 th postmole month. The longest interval between termination of mole and diagnosis of postmolar choriocarcinoma was 7 years and 2 months, the interval of which was also the longest among all of the postmolar choriocarcinoma registered to the Committee of Registration for Trophoblastic Disease in Japan Society of Obstetrics and Gynecology in 1974 through 1978. Therefore from the empirical point of view, the postmole patient should be followed up to 7 years and 2 months at the shortest. Besides almost all of the secondary sequelae after mole which were detected before urinary hCG titer fell below LH level were actually invasive mole (44 cases). Choriocarcinoma (2 cases) in this stage was exceptional (2 cases/46 cases = 4.4%). On the other hand, once the molar patient showed normal LH level in their urinary hCG determination, the secondary sequela was invariably choriocarcinoma. This way of discriminating invasive mole from choriocarcinoma is the key in the management of postmolar patient.

Adult↗
PubMed1981

Hypolipidemic effect of L-form S-methylmethionine sulfonium chloride in man.

The effect of L-form S-methylmethionine sulfonium chloride (L-MMSC) was studied in 26 patients with hypercholesterolemia during the oral administration period for 8 weeks (daily dose 1500 mg). The oral administration of L-MMSC resulted in the statistically significant decrease of serum total cholesterol (9.7%, P less than 0.001), but not of serum triglycerides. In addition, the statistically significant increases in serum high-density lipoprotein-cholesterol (HDL-cholesterol) and in the ratios of HDL-cholesterol/(total cholesterol) -- (HDL-cholesterol) and HDL-cholesterol/(total cholesterol) + (triglycerides) were observed by the administration of L-MMSC. The therapeutic effects in in-patients were more remarkable than those in outpatients.

Adult↗